MedTrace Logo

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

NCT02864407 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3223

Last updated 2022-03-28

Study results available
· View outcomes & findings →

Summary

To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)

The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-19
Primary Completion
2021-01-20
Completion
2021-01-20
FDA Drug
Yes

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02864407 on ClinicalTrials.gov